The STRIVE Study: Breast Cancer Screening Cohort

Overview

About this study

GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to train and validate an assay to detect invasive breast cancer in patients undergoing mammography.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Women undergoing mammography for screening indications or have an appointment for screening mammography.
  2. Participant provides informed consent and expresses understanding of the protocol and its requirements, risks, and discomforts.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Celine Vachon, Ph.D.

Closed for enrollment

La Crosse, Wis.

Mayo Clinic principal investigator

Richard Ellis, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

Santo Maimone, M.D.

Closed for enrollment

Eau Claire, Wis.

Mayo Clinic principal investigator

Cameron Leitch, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bhavika Patel, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions